Imaging assessment after SBRT for hepatocellular carcinoma

Abstract

The use of stereotactic body radiotherapy (SBRT) in hepatocellular carcinoma (HCC) has increased over the past few decades. Thus, accurate evaluation of post-SBRT treatment response is essential to avoid over-treatment of responders as well as missing the opportunity to salvage non-responders. There are some intricate imaging differences after liver SBRT compared to those observed after conventional fractionated radiotherapy and other locoregional treatment. We aim to review the imaging changes that occur following SBRT for HCC and their potential clinical implications.

Keywords

Imaging / liver / stereotactic body radiotherapy / hepatocellular carcinoma

References

[1] Méndez Romero A,Hussain SM,Heijmen BJM.Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study..Acta Oncol2006;45:831-7

[2] Bujold A,Kim JJ,Cho C.Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma..J Clin Oncol2013;31:1631-9

[3] Culleton S,Haddad CR,Brierley J.Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma..Radiother Oncol2014;111:412-7

[4] Andratschke N,Allgäuer M,Blanck O.The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases..BMC Cancer2018;18:283 PMCID:PMC5851117

[5] Scorsetti M,Clerici E,Tozzi A.Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up..Radiat Oncol2018;13:234 PMCID:PMC6258482

[6] Sapisochin G,Doherty M,Goldaracena N.Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis..J Hepatol2017;67:92-9

[7] Fajardo LF.The pathology of ionizing radiation as defined by morphologic patterns..Acta Oncol2005;44:13-22

[8] Reed GB.The human liver after radiation injury. A form of veno-occlusive disease..Am J Pathol1966;48:597-611 PMCID:PMC1916442

[9] Eisenhauer EA,Bogaerts J,Sargent D.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)..Eur J Cancer2009;45:228-47

[10] Bruix J,Llovet JM,Lencioni R.Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference..J Hepatol2001;35:421-30

[11] Lencioni R.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma..Semin Liver Dis2010;30:52-60

[12] Vernuccio F,Meyer M,Salama JK.Local tumor control and patient outcome using stereotactic body radiation therapy for hepatocellular carcinoma: iRECIST as a potential substitute for traditional criteria..Am J Roentgenol2019;213:1232-9

[13] Price TR,Sandrasegaran K,Maluccio MA.Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma..Cancer2012;118:3191-8

[14] Mannina EM,Lasley FD,Zook J.Role of Stereotactic body radiation therapy before orthotopic liver transplantation: retrospective evaluation of pathologic response and outcomes..Int J Radiat Oncol2017;97:931-8

[15] Takamatsu S,Kobayashi S,Yoshida K.Pathology and images of radiation-induced hepatitis: a review article..Jpn J Radiol2018;36:241-56

[16] Lall C,Sandrasegaran K,Ramsinghani N.Three-dimensional conformal radiation therapy in the liver: MRI findings along a time continuum..J Comput Assist Tomogr2015;39:356-64

[17] Park MJ,Yoon SM,Park SH.Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed tomography..PLoS One2014;9:e90327 PMCID:PMC3938667

[18] Kimura T,Takahashi I,Doi Y.The time course of dynamic computed tomographic appearance of radiation injury to the cirrhotic liver following stereotactic body radiation therapy for hepatocellular carcinoma..PLoS One2015;10:e0125231 PMCID:PMC4466204

[19] Ronot M,Paradis V,Dorvillius M.Liver fibrosis in chronic hepatitis C virus infection: Differentiating minimal from intermediate fibrosis with perfusion CT..Radiology2010;256:135-42

[20] Yu JI,Lim DH,Jung SH.The role of diffusion-weighted magnetic resonance imaging in the treatment response evaluation of hepatocellular carcinoma patients treated with radiation therapy..Int J Radiat Oncol2014;89:814-21

[21] Lo CH,Hsiang CW,Lin CS.Prognostic significance of apparent diffusion coefficient in hepatocellular carcinoma patients treated with stereotactic ablative radiotherapy..Sci Rep2019;9:14157 PMCID:PMC6775098

[22] Lee SM,Lee S.Emerging role of 18 F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma..World J Gastroenterol2019;25:1289-306 PMCID:PMC6429342

[23] Huang WY,Huang WS,Chang LP.18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy..J Nucl Med2013;54:1710-6

[24] Lu RC,Gao WT,Xu DD.Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects..World J Gastroenterol2019;25:4682-95 PMCID:PMC6718031

[25] Talbot JN,Balogova S,Kerrou K.Detection of hepatocellular carcinoma with PET/CT: A prospective comparison of 18F-Fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease..J Nucl Med2010;51:1699-706

[26] Wallace MC,Francis RJ,Ferguson J.Baseline and post-treatment 18F-Fluorocholine PET/CT predicts outcomes in hepatocellular carcinoma following locoregional therapy..Dig Dis Sci2020;65:647-57

[27] Koay EJ,Das P.Radiation-induced liver disease and modern radiotherapy..Semin Radiat Oncol2018;28:321-31 PMCID:PMC6402843

[28] Munoz-Schuffenegger P,Dawson LA.Radiation-induced liver toxicity..Semin Radiat Oncol2017;27:350-7

[29] Zuckerman E,Sabo E,Naschitz JE.Quantitative liver-spleen scan using single photon emission computerized tomography (SPECT) for assessment of hepatic function in cirrhotic patients..J Hepatol2003;39:326-32

[30] Bowen SR,Borgman J,Kinahan PE.Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients..EJNMMI Res2016;6:57 PMCID:PMC4923007

[31] Kamimura K,Yoneyama T,Tateyama A.Quantitative evaluation of liver function with T1 relaxation time index on Gd-EOB-DTPA-enhanced MRI: Comparison with signal intensity-based indices..J Magn Reson Imaging2014;40:884-9

[32] Haimerl M,Zeman F,Nickel D.Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: Comparison between signal-intensity-based indices and T1 relaxometry..Sci Rep2017;7:43347 PMCID:PMC5339723

[33] Yoon JH,Kang H,Yang H.Quantitative assessment of liver function by using Gadoxetic Acid-enhanced MRI: Hepatocyte uptake ratio..Radiology2019;290:125-33

[34] Bowen SR,Chapman TR,Kinahan PE.Differential hepatic avoidance radiation therapy: proof of concept in hepatocellular carcinoma patients..Radiother Oncol2015;115:203-10 PMCID:PMC4587568